Spike,S2 protein,Spike glycoprotein Subunit2,S glycoprotein Subunit2,Spike protein S2
SARS-CoV-2 S2 protein (T716I, S982A, D1118H), His Tag (S2N-C52Hd) is expressed from human 293 cells (HEK293). It contains AA Ser 686 - Pro 1213 (Accession # QHD43416.1). The recombinant protein is expressed from human 293 cells (HEK293) with T4 fibritin trimerization motif and a polyhistidine tag at the C-terminus. Proline substitutions (F817P/ A892P/ A899P/ A942P/ K986P/ V987P) are introduced to stabilize the trimeric prefusion state of SARS-CoV-2 S protein. The T716I/ S982A/ D1118H mutations were identified in the SARS-CoV-2 variant (known as B.1.1.7, 20B/501Y.V1 or VOC 202012/01) which emerged in the United Kingdom.
Predicted N-terminus: Ser 686
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 59.6 kDa. The protein migrates as 70-100 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Less than 1.0 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
SARS-CoV-2 S2 protein (T716I, S982A, D1118H), His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized SARS-CoV-2 S2 protein (T716I, S982A, D1118H), His Tag (Cat. No. S2N-C52Hd) at 1 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 Spike S2 protein Antibody, Human IgG4 (Cat. No. S2N-S86) ) with a linear range of 0.2-1 ng/mL (QC tested).
The ongoing SARS-COV-2 pandemics has sickened 3.7 million people around the world, claiming over 1,000,000 lives. To deal with this global public health crisis, unprecedented efforts are being made to study the virus, SARS-CoV-2. At present, there are 193 new crown vaccine projects registered with the World Health Organization are being developed. To support these studies, ACRO has developed Mouse Anti-SARS-CoV-2 antibody IgG Serologic Assay kit.
Important Licensing Information: This product may be covered by Limited Use Label License(s). By use of this product, you accept the terms and conditions of all applicable Limited Use Label License(s).
Limited Use Label License No. 18: Engineered Coronavirus Spike Proteins
This product and its use is the subject of U.S. Provisional Patent Application No. 63/032,502 and sold under a license from The University of Texas at Austin. Rights to use this product are limited to research and clinical diagnostics, and expressly exclude the right to use in human therapeutics, vaccines, and any use involving the administration of this product to humans.